NextGen Bio

Found 1,431 articles

• Motus GI Enrolls First Patient in REDUCE Study of the Pure-Vu® System in Hospitalized Patients

  5/23/2018

  Published studies show insufficient bowel prep can occur in over 55% of inpatient cases and lead to average of 2 day hospital stay extension and as much as $8,000 in additional costs

• New Data Released at European Conference Demonstrates LuViva® Advanced Cervical Scan Detects Cervical Cancer Earlier than Pap and HPV tests

  5/22/2018

  LuViva proved to be the more sensitive test, finding cervical cancer missed by Pap and HPV tests.

• 3D Systems' NextDent™ 5100 Named 2018 Healthcare Application of the Year by Additive Manufacturing Publication '3D Printing Industry'

  5/21/2018

  NextDent™ 5100 - powered by Figure 4™ technology - recognized by publication's readers for its ability to redefine digital dentistry and enhance patient care

• HedgePath Pharmaceuticals Announces Additional Expanded Patent Coverage

  5/21/2018

  HPPI's patent portfolio expands again with claims covering treatment of any non-cancerous proliferation disorders with itraconazole, the active ingredient in HPPI's current and anticipated future product candidates

• AAPA's Center for Healthcare Leadership and Management Announces Employers of Excellence

  5/21/2018

  The award program is designed to showcase hospitals and health systems that have implemented practices that create positive work environments for PAs (physician assistants) and encourage collaborative provider teams.

• Spectrum Medical Partners Continues Expanding Presence in Florida with Addition of Acute and Post-Acute Practice

  5/21/2018

  Founded in 2006 by Dr. Mahadevan, Cape Coral is one of the largest private hospitalist groups in southwest Florida and the market leader in Ft. Myers.

• 

  There Are Other Places to Form Biotech Companies than Boston or San Francisco

  5/18/2018

  Although it may be almost heresy to say it to venture capitalists and many research scientists, there are other places in the U.S. to form biotech companies than San Francisco and Boston.

• GTx Updates Phase 2 Enobosarm Clinical Trial Results in Stress Urinary Incontinence at 2018 AUA Annual Meeting

  5/18/2018

  GTx, Inc. (Nasdaq: GTXI) today released additional data supporting the durability of the response to a 12-week treatment with enobosarm 3 mg in an open-label, Phase 2 proof-of-concept clinical trial evaluating enobosarm in postmenopausal women with stress urinary incontinence (SUI)...

• Motus GI Reports 2018 First Quarter Financial Results and Provides Business Update

  5/15/2018

  Q1 2018 marked by significant corporate and clinical advancements, including successfully completing $17.5M IPO and listing on NASDAQ Capital Marke

• GTx Provides Corporate Update and Reports First Quarter 2018 Financial Results

  5/15/2018

  Top-line results from the ASTRID Trial expected early in the fourth quarter of 2018

• UCB Announces BRIVIACT® (Brivaracetam) now Approved by FDA to Treat Partial-onset (Focal) Seizures in Pediatric Epilepsy Patients

  5/14/2018

  BRIVIACT CV oral formulations are approved as a monotherapy or adjunctive therapy in patients four years of age and older with partial-onset seizures

• New Grants Totaling $2.6 Million Fund Work to Reduce Immunotherapy Side Effects

  5/10/2018

  American Cancer Society and Melanoma Research Alliance Fund Five Innovative Approaches

• 

  Lipocine Craters After FDA Rejects Testosterone Replacement Therapy Drug for the Second Time

  5/9/2018

  Shares of Utah-based Lipocine, Inc. are down more than 41 percent in premarket trading after the company announced it received a second Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its testosterone replacement therapy product.

• Catalyst Pharmaceuticals Announces First Quarter Financial Results and Corporate Update

  5/9/2018

  Catalyst Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2018 and provided a corporate update.

• Provision CARES Proton Therapy Cites Inaccuracies in Governor’s Veto Statements

  5/8/2018

  The bill specifically provides that proton therapy treatment must be prescribed by a Board-Certified Radiation Oncologist

• Motif Bio to Present Iclaprim Data at ASM Microbe 2018

  5/8/2018

  Motif Bio plc announced that two iclaprim abstracts have been accepted for presentation at the upcoming American Society For Microbiology (ASM) Microbe 2018 meeting to be held in Atlanta, GA, USA, June 7-11, 2018.

• 

  A Wave of Regenerative Therapies are Being Developed to Treat Patient Needs

  5/7/2018

  Artificial body parts have been around for some time. Patients have access to artificial limbs, hearts, eyes, skin and more thanks to the innovation of biomedical engineers. As technology improves, so do the advancements in these man-made devices.
• 

  Report Says: Legal Challenges to Pharmaceutical Patents Saw 30% Increase in 2017

  5/4/2018

  Patent fights are nothing new in the pharmaceutical industry but a new report shows that during 2017 the number of legal battles of pharmaceutical patents increased by 30 percent.

• New Movie Highlights Pharmaceutical Packaging Capabilities

  5/2/2018

  Now Screening on Pharma Packaging Solutions Website   [02-May-2018]   New Movie Highlights Pharmaceutical Packaging Capabilities Now Screening on Pharma Packaging Solutions Website CLINTON, Tenn., May 2, 2018 /PRNewswire/ -- Pharma Packaging Solutions (PPS) has a new movie of its cap

• ArisGlobal Introduces LifeSphere Safety MultiVigilance™ Pharmacovigilance Solution for China

  5/2/2018

  ArisGlobal announced that the China FDA, Center of Drug Evaluation has selected and implemented LifeSphere Safety MultiVigilance solution for clinical safety and pharmacovigilance (PV) through its local partners.